What is Zenflow?
Zenflow is a privately held medical device firm founded by Stanford University Biodesign Fellows in collaboration with leading urologists. The company's mission is to address the unmet needs of patients suffering from enlarged prostate, a condition causing urinary obstruction. Their proprietary Spring® technology, designed with patient experience at its core, utilizes a small, spring-like coil to gently prop open the urethra, restoring normal function while preserving anatomical integrity. The Zenflow Spring System is currently an investigational device, not yet approved for commercial sale, highlighting the company's stage of development and regulatory pathway.
How much funding has Zenflow raised?
Zenflow has raised a total of $79.4M across 3 funding rounds:
Series A
$31.4M
Series B
$24M
Series C
$24M
Series A (2018): $31.4M with participation from Medical Technology Venture Partners, F-Prime Capital Partners, and Invus Opportunities
Series B (2021): $24M led by Astia, Medical Technology Venture Partners, F-Prime Capital Partners, Invus, SV Tech Ventures, Cloudstone Capital, and Golden Seeds
Series C (2024): $24M supported by Invus, F-Prime Capital Partners, and Cook Medical
Key Investors in Zenflow
Medical Technology Venture Partners
Medical Technology Venture Partners is a venture capital firm specializing in investments within the medical technology sector, likely focusing on innovative devices and solutions that address significant healthcare challenges.
F-Prime Capital Partners
F-Prime Capital Partners is a venture capital firm that invests in healthcare and technology companies, with a strong emphasis on early-stage innovation and companies poised for significant growth.
Invus Opportunities
Invus Opportunities is an investment firm that provides capital and strategic support to companies across various sectors, likely with a focus on growth-stage enterprises.
What's next for Zenflow?
The substantial enterprise-level funding, culminating in a recent major strategic investment, positions Zenflow for significant growth and advancement. This capital infusion is expected to fuel further research and development, support clinical trials, and prepare for potential commercialization of the Zenflow Spring System. The company's focus on a patient-centric approach and its collaboration with medical professionals suggest a strategic trajectory aimed at disrupting the current treatment landscape for benign prostatic hyperplasia (BPH). Future developments will likely involve navigating regulatory approvals and scaling manufacturing to meet anticipated market demand.
See full Zenflow company page
